PDF herunterladen
Semin Liver Dis 2003; 23: 029-034
DOI: 10.1055/s-2003-41632
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Viral Kinetics in Hepatitis C Virus: Special Patient Populations

Jennifer E. Layden-Almer, Thomas J. Layden
  • University of Illinois at Chicago, Chicago, Illinois
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
21. August 2003 (online)

    Lizenzen und Reprints

ABSTRACT

The evolution in therapy for chronic hepatitis C virus (HCV) infection to the more recent use of peginterferons in combination with ribavirin has dramatically increased the sustained virological response (SVR) rates versus standard interferon/ ribavirin combination therapy. However, although peginterferon and ribavirin therapy has markedly improved treatment responses overall, factors such as high viral load, genotype 1 infection, obesity, HIV co-infection and African American race continue to pose challenges to optimizing SVR rates. Application of mathematical models may be helpful in understanding why these groups and/or individuals appear to be resistant to interferon (IFN)-based therapy. This article focuses on the viral kinetics and viral kinetic differences among patients infected with HCV genotypes 1 and 2, obese and nonobese patients, and African Americans and Whites.

KEYWORDS

Viral kinetics - mathematical modeling - peginterferon - ribavirin - chronic hepatitis C virus infection - HIV/HCV co-infection - genotype 1 - African Americans - obesity

REFERENCES

  • 1 Davis G L, Balart L A, Schiff E R. et al . Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group.  N Engl J Med . 1989;  321 1501-1506
    PubMedSuche in Google Scholar
  • 2 Fried M W, Shiffman M L, Reddy K R. et al . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.  N Engl J Med . 2002;  347 975-982
    CrossrefPubMedSuche in Google Scholar
  • 3 Zeuzem S, Feinman V, Rasenack J. et al . Peginterferon alfa-2a in patients with chronic Hepatitis C.  N Engl J Med . 2000;  343 1666-1672
    CrossrefPubMedSuche in Google Scholar
  • 4 Manns M P, McHutchison J G, Gordon S C. et al . Peginterferon alfa-2b in combination with ribavirin compared with interferion alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomized trial.  Lancet . 2001;  358 958-965
    CrossrefPubMedSuche in Google Scholar
  • 5 Heathcote J, Shiffman M, Cooksley G. et al . Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.  N Engl J Med . 2000;  343 1673-1680
    CrossrefPubMedSuche in Google Scholar
  • 6 Reddy K R, Hoofnagle J H, Tong M J. et al . Racial differences in response to therapy with IFN in chronic hepatitis C.  Hepatology . 1999;  30 787-793
    CrossrefPubMedSuche in Google Scholar
  • 7 McHutchison J G, Poynard T, Pianko S. et al . The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group.  Gastroenterology . 2000;  119 1317
    PubMedSuche in Google Scholar
  • 8 Kinzie J L, Naylor P H, Nathani M G. et al . African Americans with gentoype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians.  J Viral Hepatitis . 2001;  8 264-269
    PubMedSuche in Google Scholar
  • 9 Ho D D, Neumann A U, Perelson A S. et al . Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.  Nature . 1995;  373 123-126
    CrossrefPubMedSuche in Google Scholar
  • 10 Perelson A S, Neumann A U, Markowitz M. et al . HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time.  Science . 1996;  271 1582-1586
    PubMedSuche in Google Scholar
  • 11 Wei X, Ghosh S K, Taylor M E. et al . Viral dynamics in human deficiency virus type 1 infection.  Nature . 1995;  373 117-122
    CrossrefPubMedSuche in Google Scholar
  • 12 Nowak M A, Bonhoeffer S, Hill A. et al . Viral dynamics in hepatitis B infection.  Proc Natl Acad Sci U S A . 1996;  93 4398-4402
    CrossrefPubMedSuche in Google Scholar
  • 13 Zeuzem S, de Man A R, Honkoop P. et al . Dynamics of hepatitis B virus infection in vivo.  J Hepatology . 1997;  27 431-436
    CrossrefPubMedSuche in Google Scholar
  • 14 Tsiang M, Rooney J F, Toole J J, Gibbs C S. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy.  Hepatology . 1999;  29 1863-1869
    CrossrefPubMedSuche in Google Scholar
  • 15 Lewin S R, Ribeiro R M, Walters T. et al . Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.  Hepatology . 2001;  34 1012-1020
    CrossrefPubMedSuche in Google Scholar
  • 16 Zeuzem S, Schmidt J M, Lee J H. et al . Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo.  Hepatology . 1996;  23 366-371
    PubMedSuche in Google Scholar
  • 17 Lam N P, Neumann A U, Gretch D R. et al . Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa.  Hepatology . 1997;  26 226-231
    PubMedSuche in Google Scholar
  • 18 Neumann A U, Lam N P, Dahari H. et al . Hepatitis C viral dynamics in vivo and the antiviral efficacy of IFN-α therapy.  Science . 1998;  282 103-107
    CrossrefPubMedSuche in Google Scholar
  • 19 Zhu H, Nelson D, Crawford J, Liu C. Interferon alpha induced antiviral activity in Hepatitis C viral replicon cell cultures (Abst).  Hepatology . 2001;  34 347A
    PubMedSuche in Google Scholar
  • 20 Jessner W, Gschwantler M, Steindl-Munda P. et al . Primary IFN resistance and treatment response in chronic hepatitis C infection: a pilot study.  Lancet . 2001;  358 1241-1242
    CrossrefPubMedSuche in Google Scholar
  • 21 Layden T J, Layden J E, Reddy K R. et al . Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C.  J Viral Hepatitis . 2002;  9 334-339
    CrossrefPubMedSuche in Google Scholar
  • 22 Layden J E, Layden T J, Reddy K R. et al . First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline.  J Viral Hepatitis . 2002;  9 340-345
    CrossrefPubMedSuche in Google Scholar
  • 23 Neumann A U, Lam N P, Dahari H. et al . Differences in viral dynamics between genotypes 1 and 2 hepatitis C virus.  J Infect Dis . 2000;  182 28-35
    CrossrefPubMedSuche in Google Scholar
  • 24 Lam N P, DeGuzman L J, Pitrak D, Layden T J. Clinical and histologic predictors of response to interferon-alpha in patients with chronic hepatitis C viral infection.  Dig Dis Sci . 1994;  39 2660-2664
    PubMedSuche in Google Scholar
  • 25 Davis G L, Lindsay K, Albrecht J. et al . Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy Group.  J Viral Hepat . 1994;  1 55-63
    PubMedSuche in Google Scholar
  • 26 Pawlotsky J M, Roudot-Thoraval F, Bastie A. et al . Factors affecting treatment responses to interferon-alpha in chronic hepatitis C.  J Infect Dis . 1996;  174 1-7
    PubMedSuche in Google Scholar
  • 27 Lam N P, Pitrak D, Speralakis R. et al . Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C.  Dig Dis Sci . 1997;  42 178-185
    CrossrefPubMedSuche in Google Scholar
  • 28 Neumann A U, Reddy R, Levy-Drummer R. et al . IFN pharmacokinetics and host factors: effects on hepatitis C genotype 1 viral kinetics during treatment with CIFN.  Hepatology . 2000;  32 4
    PubMedSuche in Google Scholar
  • 29 Layden J E, Reddy K R, Kozlowski M. et al . Differences in viral kinetic parameters in response to IFN treatment between African Americans and Caucasians infected with genotype 1 virus (Abst).  Hepatology . 2001;  34
    PubMedSuche in Google Scholar
  • 30 Layden-Almer J E, Ribeiro R M, Wiley T E. et al . Viral dynamics and response differences in HCV infected African Americans and Caucasians treated with IFN and ribavirin.  Hepatology . 2003;  37 1343-1350
    CrossrefPubMedSuche in Google Scholar